Return to program book search
BCC in the Age of Targeted Therapy
Sunday, March 03
1:00 PM - 3:00 PM
Aleksandar Sekulic, MD, FAAD
- Nicole Basset-Seguin, MD, PhD - Handout
- David R. Bickers, MD, FAAD
- Anne Lynn S. Chang, MD, FAAD
- Steven A. Nelson, MD, FAAD
Following this course, the attendee should be able to:
- Review clinical features and pathogenesis of basal cell carcinoma.
- Describe the role of the hedgehog signaling pathway in basal cell carcinoma and its implication for treatment of BCC.
- Evaluate the utility of targeted therapy in treatment of BCC and discuss its benefits and challenges.
BCC, the most common human cancer, is surgically curable in most cases. However, a fraction of BCC tumors may progress to locally advanced (laBCC) or even metastatic (mBCC) stage. Historically, such patients faced dismal therapeutic choices. Recent progress in understanding the molecular pathogenesis of BCC has enabled development of novel targeted therapies. This forum will provide an update on the targeted treatments in BCC with a particular emphasis on the inhibition of the “Hedgehog” signaling pathway. Clinical progress and the challenges associated with targeted therapy in BCC will be reviewed and future directions explored.
|Sunday, March 03|
|1:00 PM||Introduction / Dr. Sekulic|
|1:05 PM||Clinical spectrum of BCC / Dr. Basset-Seguin|
|1:25 PM||The Hedgehog Pathway / Dr. Nelson|
|1:45 PM||Hedgehog pathway inhibition in a BCC / Dr. Chang|
|2:05 PM||Hedgehog pathway inhibition in BCNS / Dr. Bickers|
|2:30 PM||Challenges and future directions / Dr. Sekulic|
|2:45 PM||Panel Discussion / All faculty|